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INTRODUCTION
Although the discovery of first adipose-derived endocrine 
factor, the serine protease adipsin, is traced back to 1987 
(1), it was the discovery of leptin in 1994 (2) that centered 
many studies on the secretory function of adipose tissue, thus 
defining a new field of study, adipobiology: the study of the
molecular and cellular biology of the normal and diseased 
adipose tissue and related disorders (3-13). These studies’ 
results have indeed shifted the paradigm of adipose tissue from 
a simple energy storage to a major body’s endocrine organ. 
The adipose-secreted products include an increasing number 
of signaling proteins, conceptually designated adipocytokines 
(14,15) or adipokines (3-13,16-20), the latter terminology 
being more accurate because not solely adipocytes, but even 
in a greater capacity, non-adipocytes of adipose tissue (such as 
matrix cells, stromovascular cells and associated macrophages 
and mast cells) are sources of adipose cytokines (adipokine) 
whereas adipocyte-derived cytokines (adipocytokines) should 
be considered members of the adipokine family of proteins, 
as defined from a cell-topological viewpoint. Functionally, 
adipokines are involved in the regulation of a wide range of 
biological processes far beyond lipid, glucose and energy 
metabolism.
 In this review, we attempt to present the secretory nature 
of adipose tissue cells, and emphasis on the implications of 
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adipokines in the pathogenesis of a large number of diseases. In 
addition to the many excellent reviews that have been written 
recently (3,5-20), including about perivascular adipose tissue 
(21-26) and obesity (27,28), the aim of our review is also to 
further describe how the knowledge of adipose tissue secretion 
may be explored in studying adipopharmacology of diseases, 
particularly cardiometabolic diseases such as atherosclerosis, 
hypertension, metabolic syndrome, obesity, type 2 diabetes 
mellitus, and lipodystrophy. 
ADIPOSE TISSUE 
In mammals including humans, there are two major subtypes 
of adipose tissue: white and brown adipose tissue, WAT and 
BAT, respectively (5,29-35). WAT has a couple of subdivisions, 
each with unique anatomic, metabolic and secretory proper-
ties: intra-abdominal or visceral and subcutaneous adipose 
tissue. Visceral adipose tissue is subdivided into intraperito-
neal and retroperitoneal compartments. Intraperitoneal fat is 
itself composed of omental and mesenteric adipose tissues, 
comprising the majority of visceral fat. Importantly, in ad-
dition to the subcutaneous and visceral compartments, there 
are many small visceral depots associated with heart, blood 
vessels, major lymph nodes, ovaries, mammary glands, eyes, 
and bone marrow. 
 Although less developed in adult humans, BAT is recently 
also appreciated in adipobiology of disease (29-35). Along 
with its pivotal involvement in thermogenesis, a signature 
performance of brown adipocytes, white-to-brown adipocyte 
transdifferantiation may occur within the WAT. Likewise, 
various functions of WAT could be executed by brown adipose 
cells. 
SECRETION BY ADIPOSE TISSUE CELLS
The endocrine role of adipose tissue was mentioned first in the
late 1980’s (1). Recent transcriptomic and proteomic analyses 
revealed that more than hundred secretory proteins are syn-
thesized, stored, and released  by adipose tissue including adi-
ponectin, leptin, resistin, tumor necrosis factor-alpha (TNF-α), 
angiotensinogen, visfatin, adipsin, complement C3, comple-
ment B, acylation-stimulating protein, retinol-binding protein 
(RBP), interleukin (IL)-1β, IL-6, IL-8, IL-18, plasminogen 
activator inhibitor-1 (PAI-1), fasting-induced adipose factor, 
fibrinogen-angiopoietin-related protein, metallothionein-1-3,
tissue factor (TF), haptoglobin, pigment epithelium-derived 
factor (PEDF), hippocampal cholinergic neurostimulating 
peptide, neutrophil gelatinase-associated lipocalin, and adipo-
nutrin. Moreover, lipoprotein lipase (LPL), apolipoprotein E 
(apoE), cholesteryl ester transfer protein (CETP), nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), 
hepatocyte growth factor (HGF), heparin-binding epidermal 
growth factor (HBEGF), transforming growth factor-beta 
(TGF-β), vascular endothelial growth factor (VEGF), mono-
cyte chemoattractant protein (MCP)-1, apelin, zinc-alpha2 
glycoprotein (also named lipid mobilizing factor), agouti 
protein and various extracellular matrix proteins including 
entactin/nidogen, collagen VIα3, fibronectin, and sulfatase
2, a member of the family of matrix endosulfatses that are 
able to remodel heparan sulphate proteoglycans (34), which 
altered function is implicated in diabetes (34 and references 
therein). These adipokines provide communication between 
adipose tissue and the rest of the body, and thus exerting many 
biological effects on various organs including the brain (27), 
immune cells (9,13,19,20), heart and  blood vessels (14,15,21-
26),  liver, reproductive system, skeletal muscles, bone,  and 
also related to the pathogenesis of many diseases (3-28). 
 Although WAT and BAT both express many of the same 
adipocyte-specific genes for lipid synthesis and hydrolysis as
well as secreted adipokines, significance and impact shows
differences according to the type of adipose tissue, including 
between visceral and subcutaneous WAT. For example, leptin 
is expressed in brown adipocytes but only under condition 
of inactivity and atrophy (30). Conditions associated with 
activation of BAT, such as cold, decreases the leptin gene 
expression, often down to undetectable levels, whereas inac-
tivating conditions increases it. The expression is accordingly 
negatively regulated via β3-adrenoceptors (35). Adiponectin 
is also expressed in both WAT and BAT and similarly to the 
case for leptin, its expression is diminished by adrenergic 
stimulation (35). Visfatin is detected in the plasma and its 
concentration correlates with intra abdominal fat mass but not 
with subcutaneous fat mass (36). Subcutaneous adipose tissue 
presents higher TNF-α expression than omental fat depots and 
omental fat produce 3-fold more IL-6 than subcutaneous adi-
pose tissue (37). Analysis of WAT mRNAadiponectin and protein 
suggest that subcutaneous adipose tissue expresses higher 
levels of hormone in non-diabetics, while the expression is 
reduced in omental fat. However, the subcutaneous fat depot 
of diabetic patients expresses less adiponectin irrespective of 
adiposity. 
 Excess and deficiency of adipose tissue is a dilemma, and
interestingly leads to similar consequences, which are as-
sociated with severe insulin resistance, hypertriglyceridemia, 
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atherosclerosis and hepatic steatosis (38-40). Thus, the adi-
pocyte is emerging as a major drug target due to its central role 
in a vast array of pathophysiological processes that include 
obesity, diabetes, inflammation, coronary artery disease (CAD)
and cancer.
DISSECTING ADIPOSE SECRETORY PUZZLE INTO PIECES
The first discovered piece: adipsin (complement 
factor D) 
In 1987, adipsin, a serine protease/complement factor D, was 
the first described adipocyte-derived endocrine factor (1). On-
wards, it has been shown that murine 3T3-F442A adipocytes 
secrete complements D, C3, and B, the three essential compo-
nents of the alternative pathway (41,42). Based on the study 
of adipsin in mice, Choy et al (43) and Choy and Spiegelman 
(44) suggested that there might be a link between the activation 
of the alternative complement pathway and adipose tissue 
metabolism. The reports on genetic (ob/ob, db/db and fa/fa) 
and drug-induced obesity showed that mRNAadipsin levels in 
adipose tissue as well as plasma adipsin concentrations were 
reduced (45). Contrarily, in diet-induced obesity in mice and 
rats and in human obesity, the levels of adipsin increased in a 
positive correlated manner with the body mass index (BMI). 
It is possible that adipsin may influence adipose tissue lipid
metabolism indirectly (46). However, the exact role of adipsin 
in adipose tissue still remains unclear. 
    In addition to adipsin, there are several adipose tissue-derived 
complement components that suggest previously unsuspected 
links between energy balance and immunity. It has been shown 
that complement components C2, C3, C4, C7, and Factor B 
had higher expression in omental compared with subcutaneous 
adipose tissue. In addition, adipsin and the classical pathway 
components C1QB, C1R, and C1S were expressed in both 
depots (47). The activation of the alternative complement 
pathway results in the interaction of complement C3 with acti-
vated factor B and the enzyme adipsin, cleavage of the protein 
C3 into C3a and C3b and, ultimately, desaggregation of C3a 
to produce ascylation-stimulating protein (ASP), an adipose 
tissue-secreted factor that influences the rate of triacylglycerol
(TG) synthesis in adipose tissue (48). Also, ASP increases 
glucose transport through its effects on glucose transporter 
translocation (GLUT-1, GLUT-3 and GLUT-4) (46). 
 Of note, a collagenous repeat containing sequence of 26 
kD protein (CORS-26), dubbed “cartonectin”, was recently 
identified in cultured adipocytes (49). 
The most abundant and pleiotropic piece: 
adiponectin
Adiponectin, also known as APM1 (Adipose most abundant 
gene transcript), adipocyte complement related protein of 30 
kD (Acrp30), or adipoQ, is an adipose tissue-specific protein
of 244 amino acids sharing significant similarity with collagens
type VIII and type X, and complement protein C1q (hence the 
name adipoQ) (50,51). Interestingly, the three-dimensional 
structure of the C terminal globular domain of adiponectin has 
homology to that of TNF-α (52). However, the physiological 
effects of the two proteins are very different from each other, 
and some of the effects of TNF-α are in fact the opposite of 
those of adiponectin. In addition, adiponectin reduces the 
production and activity of TNF-α (6,19,53).
 The discovery of adiponectin occurred at about the same 
time as the discovery of leptin (1994-1996), but it did not 
receive major attention in the scientific community those 
days. Nevertheless, to date, it is the most promising adipoki-
ne with a sincere potential for developing novel intervention 
strategies for various disorders (5,17,54). Adiponectin exerts 
pleiotropic beneficial effects including anti-inflammatory, anti-
atherogenic, anti-diabetic, and anti-fibrotic. The cloning of two
adiponectin receptors, AdipoR1 and AdipoR2, was recently 
reported (55-61). AdipoR1 is abundantly expressed in muscle, 
whereas AdipoR2 is predominantly expressed in the liver. It 
has been shown that there is a fat depot specific regulation
of AdipoR1 and AdipoR2 gene expression by fasting in both 
WAT and BAT. In addition, it has been identified a coordinated 
circadian pattern of AdipoR1 and AdipoR2 gene expression in 
these tissues. The expressions of AdipoR1/R2 in insulin target 
tissues appear to be inversely correlated with plasma insulin 
levels. Insulin negatively regulates the expression levels of 
adiponectin receptors via the PI3-kinase/Foxo1 pathway. The 
data also suggest that not only the agonism of AdipoR1/R2 
but also strategies to increase AdipoR1/R2 may be logical 
approaches to provide a novel treatment modality for type 
2 diabetes, inflammation (60-65) and liver cirrhosis (66,67). 
Because decreased levels of adiponectin may contribute to 
several severe complications in type 2 diabetic individuals. 
For instance, chronic treatment with recombinant adiponectin 
increases insulin sensitivity in insulin resistant mice (61-63), 
whereas treatment with thiazolidinedione (TZD) anti-diabetic 
drugs, ligands of the nuclear transription factor peroxisome 
proliferator-activated receptor-gamma (PPARγ), also results 
in an enhanced adiponectin secretion (64). Notably, adiponec-
tin is one of the major endogenous insulin sensitizing factor. 
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Besides this function, recent evidence supports adiponectin’s 
anti-inflammatory and anti-atherogenic actions. Anti-inflam-
matory activity of adiponectin is mediated by inhibition of a 
pro-inflammatory cascade involving TNF-α and IL-6 and/or
by induction of anti-inflammatory cytokines such as IL-10 and
IL-1 receptor antagonist (61,65). These effects are paralleled 
by specific effects on endothelial cell functions including
inhibition of TNF-α-stimulated adhesion of monocytes on 
endothelial cells (57). 
 As indicated above (66,67), adiponectin also exerts anti-
inflammatory and anti-fibrotic effects in the liver, and its
deficiency might be related to liver disease progression, for
example, in non-alcoholic steatohepatitis. An anti-fibrotic ef-
fect of adiponectin has been suggested on the basis of AdipoR 
gene expression in hepatic stellate (Ito’s) cells, and the inhibi-
tion of these cell proliferation and migration after adiponectin 
treatment. 
 Adiponectin suppresses TNF-α–induced nuclear factor 
kappa B (NF-κB) activation in human aortic endothelial cells 
via a cAMP-dependent pathway (68). However, angiotensin 
II-induced human endothelial cell apoptosis can be prevented 
by adiponectin through promotion and stabilization of the as-
sociation between eNOS and Hsp90 (69). Further, adiponectin 
exerts a preventive effect on vascular stenosis in the injured 
artery (70-72). Growing body of evidence indicates that 
adiponectin has anti-atherogenic role. It has been shown that 
hypoadiponectinemia increases prevalence and magnitude 
of systemic atherosclerosis including ischemic heart disease 
and arteriosclerosis obliterans. Related in vivo studies have 
shown that adiponectin can suppress the development of athe-
rosclerosis in susceptible mice. Indeed, ApoE-deficient mice 
treated with recombinant adenovirus to increase the circulating 
levels of adiponectin demonstrated a 30% decrease in lesion 
formation compared with mice expressing a control protein 
(72). Adiponectin associated with foam cells in the fatty streak 
lesions, suppressed the expression of vascular cell adhesion 
molecule-1 and class A scavenger receptors, and tended to 
reduce levels of TNF-α. 
 Adiponectin is as a negative regulator of angiogenesis. It 
is a direct angiogenesis inhibitor that induces apoptosis in 
activated endothelial cells (73). In vitro, it inhibits endothelial 
cell proliferation and migration. Further, endothelial-related 
mechanisms involve activation of caspase mediated apopto-
sis. Adiponectin induces a cascade activation of caspases-8, 
-9 and –3, which leads to cell death. In mouse tumor model, 
adiponectin inhibits primary tumor growth. Recently, it has 
been shown that adiponectin decreases breast cancer cell pro-
liferation by inhibiting the entry of cells into S-phase without 
inducing apoptosis (74). In this regard, adiponectin and its 
receptors may be effective anti-cancer factors with therapeutic 
implications for angiogenesis-dependent diseases.
 Adiponectin expression and circulating protein levels are 
decreased in obesity (75). Plasma adiponectin levels have been 
previously reported to be correlated negatively with BMI and 
waist-to-hip ratio (WHR) in human studies (76,77).  However, 
clinical studies have suggested that plasma adiponectin con-
centrations and insulin sensitivity are more closely correlated 
with intra-abdominal than with subcutaneous adipose tissue 
(78), and it was recently reported that low plasma adiponectin 
levels are most closely correlated with accumulation of pos-
terior subcutaneous abdominal adipose tissue (79).
 It has been demonstrated that the adiponectin gene is highly 
expressed in differentiated brown adipocytes and provided new 
insights into the regulation of this key hormone. Adiponectin 
transcript is not detected in undifferentiated T37i cells sug-
gesting that adiponectin gene activation occurs during the 
adipocyte differentiation process (80). Adiponectin gene ex-
pression could also be considered as markers of differentiation, 
together with the inner mitochondrial membrane uncoupling 
protein-1 (UCP-1), in the T37i cell line, since these genes were 
expressed exclusively in fully differentiated cells. These data 
therefore suggest that adiponectin plays important roles in 
brown adipocyte biology. The results are comparable to those 
obtained in the WAT since expression of adiponectin transcript 
was detected in fully differentiated murine and human white 
adipose cells. Regulatory effects of various stimuli on adi-
ponectin gene expression in brown and white adipocytes are 
found also strikingly different. For instance, insulin increases 
the adiponectin expression in brown adipocytes but not white 
adipocytes (6). These findings bring additional support for
major functional differences between the two cell types and 
suggest their distinct involvement in various physiologic and 
pathologic events. Given the major role played by adiponectin 
as factor regulating insulin sensitivity and also other biological 
processes, BAT could be seen as a novel endocrine source of 
adipokines, not only in rodents but also in humans.
The most popular piece: leptin
Leptin is a pleiotropic protein/cytokine belonging to the fam-
ily of long-chain helical cytokines and has structural similar-
ity with IL-6, IL-12, IL-15, granulocyte colony-stimulating 
factor, and oncostatin M. Leptin expresses a broad variety 
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of biological actions, including reproduction, regulation of 
hypothalamic-pituitary-adrenal axis, glucose and insulin 
metabolism, lipolysis, sympathetic nerve activity, immune 
and inflammatory responses, hematopoiesis, angiogenesis, 
bone formation, blood pressure, and wound healing (81-86). 
Leptin (from the Greek leptos meaning thin) is a cytokine 
product of the obese (ob) gene that is produced by both white 
and brown adipocytes.
 Leptin gene expression is regulated by several factors but 
mainly by food intake and hormones. For instance, insulin 
stimulates leptin secretion during feeding and a decrease of 
insulin levels precedes a fall in leptin concentrations during 
starvation in humans (81). Glucocorticoids increase leptin 
levels and this response is more robust than the response 
induced by insulin (87). Other stimulators of leptin synthesis 
are acute infection, sepsis and pro-inflammatory mediators
such as IL-1, TNF-α and leukemia inhibitory factor (84,88), 
whereas leptin levels were decreased by  β3-adrenergic activity, 
free fatty acids, growth hormone, and PPAR-γ agonists (89). 
Furthermore, the expression of this hormone is inhibited by 
testosterone, whereas it is increased by ovarian sex steroids 
(90,91).
 Several lines of evidence suggest that hyperleptinemia is 
involved in the pathogenesis of obesity-associated cardio-
vascular diseases including arterial hypertension (92-94). 
First, chronic leptin administration increases blood pressure 
in experimental animals. Second, hypertension is observed 
in transgenic mice overexpressing leptin, although their body 
weight is lower than wild-type littermates (94). Third, obesity 
is accompanied by hypertension in hyperleptinemic agouti 
yellow obese mice but not in leptin-deficient ob/ob mice. 
Finally, plasma leptin concentration correlates with blood 
pressure in hypertensive humans, also in those who are not 
obese. It has been suggested that leptin induces hypertension 
by activating the sympathetic nervous system (94). However, 
this mechanism can not solely explain the hypertensive effect 
of leptin. Recently, it has been demonstrated that leptin incre-
ases the level of systemic and intrarenal oxidative stress, and 
decreases renal sodium excretion and nitric oxide production 
in the rat. These effects may also contribute to the development 
of leptin-induced hypertension in experimental models as well 
as in hyperleptinemic obese individuals (93).
 Leptin plays an essential role in transmitting signals for 
energy status to the central nervous system (CNS). Leptin can 
cross the blood-brain barrier (BBB) to act at the arcuate nu-
cleus. A saturable transport system exists at the vascular BBB 
and choroid plexus. Failure of the leptin transporter is a major 
contributor to the development of leptin resistance in obesity. 
In humans and diet-induced obesity of outbred rodents, BBB 
resistance likely precedes resistance at the arcuate nucleus. 
BBB resistance is acquired and to some extent reversible with 
reductions in body weight induced by either fasting or leptin 
treatment (95). The BBB transporter for leptin is regulated by a 
number of substances, including epinephrine, glucose, insulin, 
and triglycerides and by events such as starvation (96).
 Leptin has potent effects on lipid metabolism, leading to a 
substantial reduction of fat mass within several days of admi-
nistration (97). Leptin has also been shown to have numerous 
actions on sites other than the central nervous system through 
high-affinity receptors located in peripheral tissue cells. Ac-
tions on hematopoietic precursor cells, cultured hepatocytes, 
pancreatic islet cells, and human marrow stromal cells and the 
recently discovered effect on chondrocytes of skeletal growth 
centers have all been reported as parts of the biological action 
spectrum of leptin. A number of tissues other than adipocytes 
secrete leptin, including the hypothalamus, stomach, intestines, 
placenta and testes (81,98-101).
 Leptin also acts acutely to increase glucose metabolism re-
gardless of its weight-reducing actions, suggesting its spectrum 
of activity is not on lipid metabolism alone but also on glucose 
metabolism (102).
 The importance of adequate nutrition for the maintenance 
of reproductive function has been well known for some time. 
Inadequate nutrition delays or prevents the onset of puberty, 
but the mechanism linking nutrition to the reproductive system 
has not been fully elucidated (103). Many studies have focused 
on leptin in the search for this possible link.  Leptin receptor 
mRNA has also as been localized to human ovaries and testes 
and has also been found in immortalized rat GnRH neurons and 
ovarian granulosa cells. Thus it appears that leptin has some 
role in the regulation of reproduction, acting both centrally 
and peripherally (98,99,104). 
 Severe lipodystrophy, caused by a deficiency or destruction
of adipose cells, is a state characterized by low leptin levels 
(39). Other abnormalities in this condition include hypertrig-
lyceridemia and severe insulin resistance, which is usually 
accompanied by diabetes mellitus (40). There are several 
genetic and acquired forms of lipodystrophy in humans, and 
studies of a variety of genetically engineered animal models 
demonstrated that the metabolic abnormalities develop as a 
consequence of fat loss (38,105). Why is adipose tissue so 
vital to the prevention of these metabolic abnormalities? One 
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hypothesis is that leptin has a critical role in preventing the 
insulin resistance and hypertriglyceridemia of lipodystrophy. 
Interestingly, leptin-replacement therapy at a level meant to 
achieve physiologic levels led to a dramatic improvement in 
insulin resistance, hyperglycemia, hypertriglyceridemia, and 
hepatic steatosis in a mouse model of lipodystrophy (106). 
Recombinant human leptin therapy improves metabolic ab-
normalities in patients with lipodystrophy and is well-tolerated 
(39). Lee and colleagues have reported that hyperleptinemia 
corrects steatosis in a variety of organs that act as sites of 
lipid accumulation, such as liver, islet cells, and heart in diet-
induced obesity (107). 
 Additional information about leptin and its mechanisms 
of actions should help the development of safe and effective 
pharmacological treatments of obesity and related cardio-
cascular disorders. Leptin has effects on vascular tissue and 
is associated with arterial wall thickness, decreased vessel 
distensibility, and elevated  C-reactive protein levels (108). 
Leptin has also procoagulant and antifibrinolytic properties,
and it promotes thrombus and atheroma formation, probably 
through the leptin receptors by promoting vascular inflam-
mation, proliferation, and calcification, and by increasing
oxidative stress.
 Leptin promotes proliferation and differentiation of hema-
topoietic cells, alters cytokine production by immune cells, 
stimulates endothelial cell growth and angiogenesis, and 
accelerates wound healing. Leptin normalizes the suppressed 
immune function associated with malnutrition and leptin 
deficiency (109). It is well established that genetic defects in 
the leptin/leptin receptor system in mice are associated with 
thymus atrophy, impairment of the delayed-type hypersensiti-
vity reaction a decreased number of circulating lymphocytes, 
intraepithelial lymphocytes in the intestinal mucosa and natural 
killer cells (NK) in the liver, spleen, lung and peripheral blood 
(110). An important role for leptin in bone development is 
supported by the observation that leptin-deficient ob/ob mice 
have skeletal abnormalities which can be prevented by cent-
ral leptin administration. Hipothalamic leptin has permissive 
effect on normal bone growth (101).
 It has been shown that BAT expresses only leptin, under 
conditions of inactivity and atrophy (30). Thus, conditions 
associated with activation of brown adipose tissue such as cold 
and increased sympathetic nerve activity, decrease leptin gene 
expression in brown adipose tissue. It might be reasonable to 
speculate that cold induced decreased leptin may involve the 
regulation of increased appetite during cold.
 The hormonal regulation of brown adipocyte secreted leptin 
clearly differs from that observed in WAT (33). Insulin is a 
stimulator of leptin synthesis and exerts its effects mostly 
through a strong, rapid, and transient activation of leptin 
transcription. However, glucocorticoids inhibit insulin action 
in T37i cells, pointing to specific molecular mechanisms that 
account for the tissue specificity of leptin gene expression. It is 
suggested that leptin might exert direct and significant effects 
on brown adipocytes, most notably related to thermoregulation 
and energy expenditure, through an autocrine pathway.
The enigmatic piece: resistin 
Resistin was discovered in 2001 and its precise biological role 
especially for humans remain to be settled (111). It appears to 
be involved in adipogenesis, and is hypothesized to be a link 
between obesity and insulin resistance- both conditions known 
to be associated with atherosclerois (112-114). Resistin is not 
only expressed in adipocytes, it is also highly expressed in 
monocytes/macrophages which makes it a pro-inflammatory
molecule (113-116). It is a member of the newly-discovered 
family of cysteine-rich secretory proteins called resistin-like 
molecules (RELM) or found in inflammatory zone (FIZZ).
The third member of the family (FIZZ-3), resistin, is expressed 
exclusively in white adipose tissue with the highest levels in 
gonodal fat. Resistin mRNA does not exist in any other mouse 
tissue including BAT. For the rats, resistin expression occurs 
mainly in white, but relatively in much lower amounts in brown 
adipose tissue (6,117). 
 Three major physiological processes have been proposed as 
targets for  resistin actions: glucose metabolism, adipogenesis, 
and  inflammation (118). Initial studies have demonstrated 
that obesity induced by a high-fat diet, mutation of the leptin 
gene (ob/ob mice) or leptin receptor gene (db/db mice), is 
associated with elevated circulating resistin concentrations. 
Intraperitoneally-administered resistin elevates blood glucose 
and insulin concentration in mice, and impairs hypoglycemic 
response to insulin infusion. In addition, anti-resistin antibod-
ies decrease blood glucose and improve insulin sensitivity in 
obese mice. Resistin suppresses insulin-stimulated glucose up-
take in cultured 3T3-L1 adipocytes, and this effect is prevented 
by anti-resistin antibodies. These data suggest that resistin 
induces insulin resistance and hyperresistinemia contributes 
to impaired insulin sensitivity in obese rodents (111). Resistin 
induces suppressor of cytokine signaling 3 (SOCS-3),  in a 
time- and dose-dependent manner in cultured adipocytes as 
well as in adipose tissue and that inhibition of  SOCS function 
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impairs resistin action. SOCS-3 may be a cellular mediator of 
the ability of resistin to antagonize insulin action in adipocytes 
(117). The suppressive effect of TZDs on resistin secretion 
found in some studies may contribute to the insulin-sensitiz-
ing effect of this class of drugs. However, other data do not 
confirm these results (118,119). In addition, TNF-α, which is 
upregulated in obesity, suppresses resistin gene expression 
and protein secretion by 3T3-L1 adipocytes (120). 
 Resistin, similar to leptin, besides its peripheral activities 
in the regulation of energy metabolism, could be involved in 
the CNS mechanisms of feeding, by inhibiting dopamine and 
norepinephrine release in the rat hypothalamus (121). Recently 
it has been shown that hypothalamic resistin induces hepatic 
insulin resistance in rats (122). 
 The role of resistin in humans is less certain. Clinical stu-
dies in humans do not show a consistent link between resistin 
levels and either obesity or insulin resistance. There is also 
controversy regarding the importance of adipocytes as a 
source of resistin in human (123-125). Resistin is expressed 
in stromovascular fraction of WAT and in peripheral blood 
monocytes, but its mRNA is not detectable in human adipose 
cells even by very sensitive RT-PCR method, either in lean 
or in insulin resistant, obese and diabetic patients. Species 
differences in cellular resistin distribution may be partially 
explained by recent observation that in humans, in contrast to 
rodents, resistin is highly expressed in cultured preadipocytes 
but barely detectable in mature adipose cells (6). 
 Resistin accumulates locally in the inflammated joints of
patients with rheumatoid arthritis and its levels correlate with 
the intensity of inflammation as defined by the intra-articular
white blood cell count and IL-6 levels. The studies on the role 
of resistin in the inflammatory process reveal that it exhibits
potent proinflammatory properties and that resistin is able to
induce arthritis when injected into healthy mouse joints. In 
addition, it is an important regulatory cytokine triggering the 
release of other proinflammatory cytokines such as TNF-α, 
IL-1β, and IL-6. It has been demonstrated that the proinflam-
matory effects of resistin are mediated through the NF-κB 
signaling pathway (115).
 Resistin has been examined specifically in the context of
cardiovascular disease and strongly suggested that resistin 
can play important role in development of atherosclerosis. 
It was observed that macrophages infiltrated atherosclerotic
aneurysms and secreted resistin, and that resistin induced 
the production of PAI-1 and endotelin type 1 (ET-1) by en-
dothelial cells and migration of vascular smooth muscle cells 
(112,113). 
 Differentiated brown adipocytes express resistin genes 
which is under strikingly different hormonal regulation than 
that of WAT (80). While glucocorticoids have inhibitory ef-
fect on resistin expression, insulin has stimulatory effect in 
the brown adipocytes, contrary happens in white adipocytes: 
TZDs suppress the adipose-derived resistin production, and 
their antidiabetic effect, may at least in part, be achived through 
this mechanism. However, this effect of TZDs can be seen 
only on WAT adipocytes and it has opposite effect on brown 
adipocyte. Thus, depending on the activity of BAT, the effect 
of TZDs on resistin production can be stimulatory in state of 
inhibitory.
The insulinomimetic piece: visfatin  
Visfatin (standing for visceral fat-derived factor) was initially 
identified as  pre-B-cell colony-enhancing factor, a growth fac-
tor for early stage B lymphocytes (126,127). Recently joining 
to the list of adipokines, it is detected in the blood plasma, 
visceral adipose tissue, skeletal muscle, liver, bone marrow 
and lymphocytes. Its expression regulated by molecules that 
promote insuline resistance, such as lipopolysaccharide, IL-1β, 
TNF-α, and IL-6 (36,128).The expression of mRNAvisfatin in 
visceral adipose tissue was elevated by dual, PPAR-alpha and 
PPAR-γ agonist treatments (129). So far there are contradic-
tory reports about visfatin plasma levels and visceral adipose 
tissue mass, one stating that they are not correlated there is no 
relation, and the other stating  that they are and visfatin expres-
sion in the visceral adipose tissue was found to be increased in 
obesity and in these subjects plasma consentrations of visfatin 
correlated much more strongly with the amount of visceral than 
of subcutaneous adipose tissue (36). Thus, visfatin might carry 
a keyrole for understanding the biological differences between 
visceral and subcutaneous adipose tissue. Visfatin levels are 
also increased in acute lung inflammation and sepsis, which
is accompanied by an insulin-resistant state. The biological 
properties of visfatin  are similar to the growth factor-like 
properties of some of these cytokines (i.e. it is anti-apoptotic 
and promotes cell proliferation).
 The most important and interesting aspect of visfatin is its 
exertion of insulin-mimetic effects that are dose-dependent and 
quantitatively similar to the effects of insulin itself in stimu-
lating muscle and adipocyte endosome-plasma membrane 
translocation of GLUT-4, and inhibiting hepatocyte glucose 
production. Intravenous injection of recombinant visfatin in 
mice decreases plasma glucose in a dose-dependent fashion. 
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A high dose of visfatin is also capable of reducing hypergly-
cemia in obese, insulin-resistant mice. Chronic production 
of visfatin by adenoviral vector results in diminished plasma 
glucose and insulin levels in obese mice and lean controls. 
Mice heterozygous for a targeted disruption of the visfatin 
gene have slightly but significantly increased blood glucose
and decreased glucose tolerance. In keeping with its insulin-
mimetic effects, visfatin is as effective as insulin in reducing 
hyperglycemia in insulin-deficient diabetic mice (126). The
striking fact is visfatin binds to and activates the insulin re-
ceptor, causing the receptor phosphorylation and induction 
of downstream signaling molecules. However, visfatin and 
insulin do not compete for binding to the insulin receptor, 
indicating that the two proteins are recognized by different 
regions of the receptor. Recently, McLaren et al found that 
insulin decreases and dexamethasone increases mRNAvisfatin 
in both preadipocytes and adipocytes (130). 
 These observations are of great interest and trigger a burn-
ing question in mind: can visfatin be the expected miraculous 
molecule of treatment for type 1 and 2 diabetes mellitus in 
the future? However, the physiological role and pathological 
implications of visfatin must be considered with some cau-
tion. Plasma concentrations are lower than those of insulin, 
they do not fluctuate with the nutritional state, and it has been
suggested that visfatin is released from fat cells during lysis 
rather than truly secreted (131). Visfatin facilitates adipogen-
esis and accumulation of fat in the intra-abdominal depot. Its 
paradoxical effects facilitating fat accumulation and promoting 
insulin sensitivity suggest that visfatin is either good news for 
diabetes treatment or bad news for obesity treatment (36,127). 
These reservations not withstanding, it will be of great interest 
to follow future developments regarding both the mechanisms 
of production and action of visfatin, and its possible implica-
tion in the metabolic syndrome.
THE OLD PIECES OF THE ADIPOSE SECRETORY PUZZLE 
Tumor necrosis factor-alpha 
The biological actions of TNF-α have been studied for over a 
century. TNF-α is a cytokine initially described as an endotoxin 
induced factor causing necrosis of tumors and subsequently 
shown to be identical to cachexin, a factor secreted by mac-
rophages in vitro (37,132). TNF-α is a 26-kD transmembrane 
protein, which is released into the circulation as a 17-kD solub-
le protein after extracellular cleavage by a metalloproteinase 
(133). TNF-α has two main receptors, type 1 and 2, which 
are expressed on many cells, including adipocytes (134,135). 
Thus, its actions occur in many cell types and include inflam-
mation, mitogenesis, differentiation, immune modulation and 
antitumor immunity. TNF-α has also been implicated as an 
important modulator of energy metabolism, particularly in 
adipocytes. In these cells,  TNF-α regulates the expression of 
many adipocyte genes and inhibits the differentiation program 
in adipocytes. It has also been demonstrated that it interferes 
directly to glucose homeostasis and lipid metabolism in adi-
pose tissue and contributes to the development of insulin re-
sistance in obesity and type 2 diabetes (136,137). Additionally, 
TNF-α causes reductions in the expression of genes involved 
in lipogenesis in adipocytes, likely through NF-κB mediated 
transcription (132). Although circulating TNF-α levels are 
relatively low and have no clear correlation with obesity or 
insulin resistance, tissue expression levels of TNF-α correlate 
positively with both conditions. In mice, chronic exposure of 
cells or whole animals to TNF-α induces insulin resistance, 
and treatment with TNF-α receptor antagonists neutralize 
this effect. Furthermore, mice with targeted gene deletion of 
TNF-α or its receptors showed increased insulin sensitivity 
and improved plasma free fatty acid levels (138).
Interleukin-6 
Among the interleukines in the adipose tissue, IL-6 has been 
studied most extensively. Both IL-6 and its receptor (IL-6R) 
are expressed by adipocytes and adipose tissue matrix and 
one third of circulating IL-6 originates from adipose tissue. 
Expression and secretion of IL-6 are two to three times greater 
in visceral versus subcutaneous adipose tissue  (6,37,139). 
Circulating levels of IL-6 are elevated in obesity and reduced 
after weight loss (140).  Recently, it was reported that after 
removal of adipose tissue from mice there was a marked 
upregulation of mRNAIL-6 in adipocytes. Other mediators of 
IL-6 gene expression in adipose tissue of humans are a meal 
or insulin administration (141,142).
 IL-6 has different effects on energy homeostasis in the 
periphery and the CNS. Peripheral administration of IL-6 
induces hyperlipidemia, hyperglycemia, and insulin resistance 
in rodents and humans. IL-6 also decreases insulin signaling in 
peripheral tissues by reducing expression of insulin receptor 
signaling components and inducing SOCS-3, a negative regu-
lator of both leptin and insulin signaling (143). In rodent mo-
dels of diabetes, IL-6 has been implicated in the development 
of muscle insulin resistance and β-cell apoptosis (143,144). 
In humans with type 2 diabetes, IL-6 levels are increased and 
correlate with the severity of glucose intolerance and with the 
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severity of inflammation, as indicated by the highly sensitive
C-reactive protein serum concentration (145).
 IL-6 also inhibits adipogenesis and decreases adiponectin 
secretion (143). Central administration of IL-6 increases 
energy expenditure and decreases body fat in rodents. Further-
more, transgenic mice overexpressing IL-6 have a generalized 
defect in growth, which includes reduced body weight and 
decreased fat pad weights (146).
Plasminogen activator inhibitor type 1 
PAI-1, an inhibitor of tissue plasminogen activator, is an im-
portant inhibitor of fibrinolysis also contributes to remodeling 
of the vascular architecture (147-149). It plays role in the 
pathogenesis of atherothrombosis and cardiovascular disease. 
PAI-1 is expressed by many cell types within adipose tissue 
including adipocytes (150-152). The subcutaneous fat depot 
has been shown both to exhibit a higher PAI-1 gene expression 
and to secrete greater amounts of PAI-1 than visceral adipose 
tissue. Recently, the stromal-vascular fraction has been shown 
to be the main source of PAI-1 production in human fat with 
evidence of a 5-fold higher expression in the visceral than 
in the subcutaneous depots, which is in agreement with the 
strong relationship observed between circulating PAI-1 con-
centrations and visceral fat enlargement (153).  Plasma PAI-1 
is increased in patients with central obesity and it has been 
found that abdominal adipose tissue is an important source of 
plasma PAI-1 (153). Moreover, insulin resistance may be an 
important regulator of PAI-1 level. Recently, higher levels of 
plasma PAI-1 in HIV-infected patients with HIV-associated 
lipodystrophy syndrome (HALS) have been demonstrated 
(154). There are at least three kinds of cells that may contribute 
to the level of circulating PAI-1: liver cells, endothelial cells 
and adipocytes. Plasma concentrations of PAI-1 have been 
found to be correlated positively with the amount of PAI-1 
produced by subcutaneous adipose tissue in vitro as well as 
mRNAPAI-1 concentration in subcutaneous adipose tissue in 
HALS patients.  The enhanced plasma PAI-1 may be to the 
result of increased production of PAI-1 in other cell types such 
as endothelial cells or hepatocytes, or increased production 
in other depots, for example, the enhanced visceral adipose 
depot (151).
 In human population studies, circulating PAI-1 levels cor-
relate with atherosclerotic events and mortality, and some 
studies suggest that PAI-1 may be an independent risk factor 
for coronary artery disease. Hyperglycemia, AngII, and very 
low-density lipoprotein cholesterol, in addition to obesity, 
contribute to elevated serum PAI-1 levels. All of these fac-
tors increase PAI-1 gene expression. High levels of PAI-1 in 
patients with diabetes are a major contributor to the prothrom-
botic state in diabetes, which leads to enhanced atherosclerotic 
mortality (148,149). PAI-1 is also a potential target in the 
prevention of adipose tissue accumulation. Two independent 
studies show that PAI-1 knockout mice are fully protected 
against high-fat diet-induced or genetic obesity in an ob/ob 
background (155,156). Recently an in vitro study showed that 
PPAR-γ agonists inhibited PAI-1 expression in adipose tissue 
and that antithrombotic effect was mediated by adiponectin 
(157). In the light of those data, antagonising TNF-α, Il-6 and 
PAI-1 opens a new horizon in adipopharmacology.
THE METABOTROPHIC PIECES OF THE ADIPOSE 
SECRETORY PUZZLE 
Nerve growth factor and brain-derived neurotrophic 
factor
The nerve growth factor, a prototypic member of the protein 
family of neurotrophins, was discovered by Rita Levi-Montal-
cini in 1951 (158). Studies in the past three decades initiated 
by Luigi Aloe et al have demonstrated that neurotrophins are 
not only promoters of nerve growth and survival, but also exert 
trophic effects over immune and other cell types (159). More 
recent studies demonstrate that NGF and BDNF exert me-
tabotrophic effects on glucose, lipid and energy homeostasis. 
Thus these neurotrophins as well as other neurotrophic factors 
were considered metabotrophic factors (12,28,160-164). Note 
that NGF (5,7,12,27,28,163) and BDNF (Sornelli et al, this 
voume of Biomedical Reviews) have recently been incorpo-
rated in the list of adipokines. Further, low NGF levels were 
found in patients with acute coronary syndromes (165) and 
metabolic syndrome and obesity (28,160,166,167). Accord-
ingly, a hypothesis has been raised that both NGF and BDNF 
might have therapeutic potentials for these diseases (12,28). 
Supportively, (i) NGF shares a striking structural homology 
with proinsulin and enhances glucose-induced insulin secre-
tion, (ii) NGF improves pancreatic islet transplantation, (iii) 
NGF exerts antioxidant effects, (iv) NGF upregulates PPARγ 
expression, whereas PPARγ agonists stimulate the secretion 
of adiponectin, and (v) mutations affecting Bdnf (gene encod-
ing BDNF) in mice or Ntrk2 (gene encoding the high-affinity
BDNF receptor TrkB)  are associated an increase food intake 
and severe obesity (reviewed in 12,28,161,162,164).
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Metallothioneins
Metallothioneins (MT) constitute a family of cysteine-rich 
metalloproteins, of which MT-1 and MT–2 are the best studied 
MT; they exert potent neurotrophic effects in various brain 
injuries (168). Metallothioneins (169,170) including MT-3 
(171) are also produced by adipose tissue, and exert a number 
of metabotrophic actions, such as antioxidant, antiinflamma-
tory, antidiabetic, and cardioprotecive (28,164).
 Taken together, adipopharmacology of metabotrophic factors 
might be a novel approach that may lead to the development 
of new classes of anti-obesity, anti-diabetic and anti-athero-
sclerotic drugs, a combination targeting of NGF-BDNF-adi-
ponectin-MT appearing to be a very promising approach at 
present.
CONCLUSION 
Adipose tissue has a key role in mammalian biology, but 
unlike other tissues, its mass has an almost unlimited ability 
to vary. It is now known that both increased (in obesity and 
related disorders) and decreased (in anorexia, orthorexia, and 
lipodystrophy) adipose tissue mass exert effects on immune, 
inflammatory, nervous, cardiovascular, reproductive, hemat-
opoietic and skeletal system. A better understanding of its 
implications for adipokine-mediated diseases will possibly 
open the door for discovering potentially effective therapeutic 
interventions especially for obesity and related diseases. It 
thus appears that the adipopharmacology of disease might be 
a rational scientific pursuit in future studies.
 According to the growing evidence, brown adipocytes are 
significant for human physiology although there is no discrete 
BAT depots that can be found in human adults. Investigations 
directed towards understanding the physiological role of UCP-
1 mediated thermogenesis in BAT have provided the foundati-
on for an alternative approach to antiobesity research. Impaired 
BAT activity has been associated with the development of 
obesity. Mice with increased BAT activity due to overexp-
ression of UCP-1 have enhanced energy expenditure and are 
resistant to diet-induced obesity. Transgenic mice with BAT 
ablation become obese, hyperlipidemic, and insulin resistant. 
BAT and UCP-1 is now considered as an anti-obesity weapon 
and cross-talk between BAT and WAT seems to open a new 
horizon for the treatment of obesity. An alternative approach 
exploits the plasticity of the adipose tissue by manipulating the 
expression of UCP-1 in other tissues, such as WAT or muscle. 
The observed conversion of BAT to WAT in the newborn had 
led some researchers to explore the possibility of converting 
white adipocytes back into brown in the adult. 
 It is quite likely that discrete functional specializations of 
BAT and subcutaneous and visceral WAT including organ-as-
sociated examples, such as perivascular and epicardial adipose 
tissue (21-26,172,173), should be considered in adipokine-
tergeting pharmacotherapy. Thus, both “white” and “brown” 
approaches should be pursued in the adipopharmacology of 
disease. Several therapeutic agents are around the corner and 
still others are on the horizon of “the unfinished jigsaw puzzle” 
(174) of adipose tissue secretion-related cardiometabolic and 
other diseases.
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